Colinz Laboratories reported a net profit of ₹240.12 lakh for the quarter ended June 30, 2026, marking a substantial increase from the ₹11.92 lakh recorded in the same period last year. The company’s total comprehensive income rose to ₹253.78 lakh, compared to ₹21.05 lakh in the prior year quarter. However, this financial performance was heavily influenced by non-operating items rather than core business growth, as revenue from operations declined to ₹124.09 lakh from ₹156.61 lakh in the previous year’s quarter.

The Board of Directors approved the unaudited financial results during a meeting held on July 30, 2026, in Mumbai. The results were reviewed by the statutory auditors, Vora & Associates, who conducted a limited review as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board also approved the Director’s Report, Management Discussion Report, and Corporate Governance Report for the fiscal year ended March 31, 2026.

Key Financial Metrics

What the Numbers Show

The dramatic rise in net profit was not driven by operational efficiency but by a exceptional item: a profit of ₹276.33 lakh on the sale of fixed assets. Without this one-time gain, the company’s profit before tax would have been ₹13.79 lakh, down from ₹16.07 lakh in the previous year. This indicates that while the company successfully disposed of assets, its core pharmaceutical formulation business faced headwinds, evidenced by the 20.8% decline in revenue from operations. Other income increased to ₹12.17 lakh from ₹7.52 lakh, providing some offset to the revenue drop.

Corporate Governance and Appointments

The Board approved several key administrative and governance actions. Mrs. Vijaya Mani (DIN 11363910) was appointed as a Director (Promoter & Non-Executive), liable to retire by rotation, effective from the forthcoming Annual General Meeting (AGM). Additionally, Mr. N. K. Menon (DIN 01111297) was recommended for appointment as Whole Time Director and CEO for a term of one year, from October 1, 2026, to September 30, 2027.

The company also finalized the schedule for its 40th AGM, set for September 22, 2026. The Register of Members will remain closed from September 15, 2026, to September 22, 2026. The cut-off date for determining eligible shareholders for electronic voting is September 15, 2026, with voting open from September 19, 2026, to September 21, 2026.

Auditor Appointments

In compliance with regulatory requirements, the Board appointed M/s. Sanjay Dholakia & Associates as the Secretarial Auditor for the financial year 2026-27. Furthermore, CA Ajay Ramsevak Sharma (FRN 137003W) was appointed as the Internal Auditor for the same period. These appointments were made pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, and relevant SEBI regulations.

A group of acquirers comprising Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Padam Dugar as the Person Acting in Concert (PAC), has announced a mandatory open offer to acquire up to 6,54,966 fully paid-up equity shares of Colinz Laboratories Limited . The offer represents 26% of the voting share capital of the company and is priced at ₹54 per share, aggregating to a total consideration of ₹3.53 crore.

The open offer follows the execution of a Share Purchase Agreement (SPA) dated June 18, 2026, between the acquirers and Vijaya Mani, the existing promoter and selling shareholder. Under the SPA, the acquirers agreed to purchase 8,70,500 equity shares, constituting 34.56% of the voting share capital, at a price of ₹50 per share. Upon completion of this transaction, the acquirers' shareholding will increase to 37.01%, triggering the mandatory open offer in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Offer Details

The offer price of ₹54 per share has been determined in accordance with SEBI regulations, considering the highest negotiated price under the SPA and the volume-weighted average market price. The acquirers have stated that they do not intend to delist the equity shares of the company. The offer is not conditional upon a minimum level of acceptance and is not a competitive offer.

Financial Arrangements

To fund the offer, the acquirers have opened an escrow cash account with ICICI Bank and deposited ₹89 lakh, which is more than 25% of the total offer consideration. Saffron Capital Advisors Private Limited has been appointed as the Manager to the Open Offer, while Bigshare Services Private Limited acts as the Registrar.

Tentative Schedule

The tendering period for the open offer is scheduled to commence on August 11, 2026, and close on August 24, 2026. The last date for the payment of consideration to shareholders is September 8, 2026. Public shareholders holding shares in both dematerialized and physical forms are eligible to participate in the offer through the BSE acquisition window.